Richard Pops, Alkermes chief executive, says that the company is not interested in being bought out as it nears the launch of new drugs.Photograph: Dara Mac Dónaill / THE IRISH TIMES

Dublin-based Alkermes has the low-tax domicile currently in vogue among multinational pharmaceutical companies but is not interested in being bought o(...)

Alkermes chief executive Richard Pops. Photograph: Dara Mac Dónaill / THE IRISH TIMES

Shares in Irish drug company Alkermes jumped over 10 per cent yesterday after it announced plans to seek US marketing approval for its experime(...)

Richard Pops, Alkermes chief executive, Photograph: Dara Mac Dónaill / The Irish Times

Irish biopharma group Alkermes has reported record revenues for 2013 and forecast a strong year ahead for drugs at an a(...)

Alkermes chief executive Richard Pops: “We are interested in depression, addiction, schizophrenia and pain, the big ones. Why? Because these are where governments are spending all the money.”  Photograph: Dara Mac Dónaill

When Alkermes acquired Elan’s drug technology business in Athlone in a $960 million buyout two years ago, everyone knew what it was after – or at leas(...)

Taoiseach Enda Kenny met the US investors hosted by Alkermes at an event at Guinness Storehouse. Photograph: Sasko Lazarov/Photocall

Irish biopharma business Alkermes yesterday hosted a gathering of US investors in their only Irish stop on the European tour.The group of investment f(...)

Richard Pops, chief executive of Alkermes: “Our financial results reflect the financial transformation of Alkermes.” Photograph: Aidan Crawley

Alkermes, the company that acquired Elan Drug Technologies, yesterday reported “robust” results for what it called a “remarkable year”. I(...)

Richard Pops, chief executive  of Alkermes pictured in their Dublin offices in May 2012 following the EDT deal. Photo: Aidan Crawley

Alkermes, the US company that acquired Elan’s drug manufacturing business in Athlone, announced today that it will cut almost a third of the wo(...)